USP and Public Policy
Left
Refine Your Search
USP urged the California Assembly to consider highlighting the need for quality specifications as part of the regulatory framework for California Assembly Bill AB-45 and Senate Bill SB-235, “…
Learn More
USP greatly appreciate the opportunity to provide feedback on the Cannabis Administration and Opportunity Act (CAOA) Discussion Draft.
Learn More
USP appreciates the opportunity to comment on the State of New York’s proposed rulemaking, “Addition of Part 1005 to Title 10 NYCARR (Cannabinoid Hemp).”
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA or the Agency) Guidance for Industry, Control of Nitrosamine Impurities in Human Drugs.
Learn More
USP appreciates the opportunity to comment on FDA’s draft guidance Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.
Learn More
USP appreciates the opportunity to comment on the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) draft document, Managing…
Learn More
USP appreciates the opportunity to provide comments to the Food and Drug Administration (FDA or Agency) on the “Importation of Prescription Drugs” proposed rule.
Learn More
USP appreciates this opportunity to present our comments on the competitive marketplace for biosimilars.
Learn More
USP appreciates the opportunity to provide comments on FDA’s draft guidance, “Compounding Animal Drugs from Bulk Drug Substances.”
Learn More
USP supports more transparency from the pharmaceutical industry to support a more resilient supply chain to help ensure the continued availability of safe, quality medicines.
Learn More